Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil
JCO Global Oncology · 2024
DOI: 10.1200/go-24-00354 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Rodrigo Dienstmann und 17 weiteren Autor:innen. Beteiligte Einrichtung: Oncoclínicas & CO-Medica Scientia Innovation Research (MedSir), São Paulo, Brazil. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Tissue inadequacy and operational challenges may limit lung cancer comprehensive biomarker testing. Here, we describe the initial implementation of a tailored tissue molecular journey at Oncoclínicas Precision Medicine Laboratory in Brazil, which includes fast-track (FT) non–next-generation sequencing (NGS) assays combined with a broad NGS panel. METHODS From 2021 to 2023, all nonsquamous lung cancer samples eligible for the patient support program “Lung Mapping Consortium” at Oncoclínicas & Co were evaluated using the FT panel (immunohistochemistry for PD-L1 and anaplastic lymphoma kinase [ALK], polymerase chain reaction for EGFR and BRAF , and fluorescence in situ hybridization for ROS1 ) plus a broad DNA and RNA sequencing panel of 180 genes (custom ARCHER panel). RESULTS From 1,272 samples received by the laboratory, 3% had no tissue for any molecular testing, 20% was not eligible for broad NGS panel as per pathologist assessment (tumor purity and quantity), additional 12% did not reach presequencing analytical thresholds (nucleic acid quantity and/or quality), and 3% had postsequencing failure. Most frequent alterations were KRAS mutations (28.4%, KRAS G12C 9.7%), EGFR mutations (23.6%, exon20 insertions 2.9%), ALK fusions (6.4%), MET exon 14 skipping (4.4%), ERBB2 mutations (3.4%), ROS1 fusions (3.1%), and BRAF V600E (1.9%). In 35% of the samples, FT non-NGS tests were the only molecular diagnostics: EGFR mutations (14%), ALK fusions (4.4%), ROS1 fusions (1.8%), and BRAF V600E (0.7%). Overall, high PD-L1 expression (≥50%) was found in 12.3%. CONCLUSION This study provides data on the molecular epidemiology of lung adenocarcinoma in Brazil, confirming high prevalence of EGFR mutations, ALK fusions, and MET exon 14 skipping alteration. Biomarker detection is largely affected by biospecimen collection and processing, with one third of the patients eligible for non-NGS testing only, which presents reduced coverage and sensitivity for actionable drivers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncoclínicas & CO-Medica Scientia Innovation Research (MedSir), São Paulo, Brazil.
- University of Vic-Central University of Catalonia, Vic, Spain.
- Boston Lighthouse Innovations, Boston, MA.
ORCID-Profile: Rodrigo Dienstmann, Amanda Muniz Rodrigues, Carolina de Bustamante Fernandes, Bruno Batista de Souza, Tatiane Montella, Pedro de Marchi, Breno Jeha Araújo, Carlos Gil Ferreira
Zitieren
APA
Dienstmann, R., da Silva, L. M., Orpinelli Ramos do Rego, F., Muniz Rodrigues, A., Koyama, F. C., Galindo, L. T., de Bustamante Fernandes, C., de Souza, B. B., Paes, R. D., Montella, T., de Marchi, P., Jeha Araújo, B., Ferrari, B. L., Mathias, C., Pereira, E., Zalis, M. G., Leslin, C., & Ferreira, C. G. (2024). Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil. JCO Global Oncology. https://doi.org/10.1200/go-24-00354
Vancouver
Dienstmann R, da Silva LM, Orpinelli Ramos do Rego F, Muniz Rodrigues A, Koyama FC, Galindo LT, et al. Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil. JCO Global Oncology. 2024. doi:10.1200/go-24-00354
BibTeX
@article{Dienstmann2024,
author = {Dienstmann, Rodrigo and da Silva, Leonard M and Orpinelli Ramos do Rego, Fernanda and Muniz Rodrigues, Amanda and Koyama, Fernanda Christtanini and Galindo, Layla Testa and de Bustamante Fernandes, Carolina and de Souza, Bruno Batista and Paes, Rafael Duarte and Montella, Tatiane and de Marchi, Pedro and Jeha Araújo, Breno and Ferrari, Bruno Lemos and Mathias, Clarissa and Pereira, Emilio and Zalis, Mariano Gustavo and Leslin, Chesley and Ferreira, Carlos Gil},
title = {Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil},
journal = {JCO Global Oncology},
year = {2024},
doi = {10.1200/go-24-00354}
}
EUVIMED